Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Restructuring Costs (2024 - 2026)

ArriVent BioPharma has reported Restructuring Costs over the past 3 years, most recently at $2.3 million for Q1 2026.

  • Quarterly results put Restructuring Costs at $2.3 million for Q1 2026, up 7.44% from a year ago — trailing twelve months through Mar 2026 was $8.9 million (up 17.2% YoY), and the annual figure for FY2025 was $8.8 million, up 22.77%.
  • Restructuring Costs reached $2.3 million in Q1 2026 per AVBP's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $2.4 million in Q2 2025 and bottomed at $1.5 million in Q4 2024.
  • Median Restructuring Costs over the past 3 years was $2.1 million (2024), compared with a mean of $2.0 million.
  • Peak annual rise in Restructuring Costs hit 54.86% in 2025, while the deepest fall reached 7.37% in 2025.
  • Over 3 years, Restructuring Costs stood at $1.5 million in 2024, then soared by 54.86% to $2.3 million in 2025, then grew by 2.21% to $2.3 million in 2026.
  • Business Quant data shows Restructuring Costs for AVBP at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $1.9 million in Q3 2025.